All You Need To Know About Merck’s Covid Pill Molnupiravir

Molnupiravir was developed for the treatment of Influenza. According to whistleblower complaint Molnupiravir has mutagenic properties and may change your DNA. Now, Molnupiravir has been repurposed for COVID-19. Merck has entered into agreements with Indian manufacturers and has also announced $5 million of donations to enter into Indian market. Here is all you need to know about Merck's Covid pill Molnupiravir.

[toc]

Molnupiravir was developed for Influenza

Molnupiravir (development codes MK-4482 and EIDD-2801) is an experimental antiviral drug which is orally active and was developed for the treatment of influenza.

It is a prodrug of the synthetic nucleoside derivative N4-hydroxycytidine, and exerts its antiviral action through introduction of copying errors during viral RNA replication.

The drug was developed at Emory University by the university's drug innovation company, Drug Innovation Ventures at Emory (DRIVE).

It was then acquired by Miami-based ...

Limited Time

Full Access

$10
Monthly

Included:

  • Access to All Articles.
  • One Plan. No Tiers.
  • No Ads.
  • Cancel anytime.
register now

 
Do you have a tip or sensitive material to share with GGI? Are you a journalist, researcher or independent blogger and want to write for us? You can reach us at [email protected].